Ftse Mib
33.768,95
-0,05%
DAX
19.884,75
-0,57%
S&P 500
5.956,10
1,52%
NASDAQ
19.635,23
1,35%
Bitcoin
97.485,11
0,02%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MaxCyte Inc (MXCT) MaxCyte Inc (MXCT) Notizie

MXCT

MaxCyte (MXCT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MXCT
DataOraFonteTitoloSimboloCompagnia
10/12/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
09/12/202414:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MXCTMaxCyte Inc
09/12/202408:00GlobeNewswire Inc.MaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceNASDAQ:MXCTMaxCyte Inc
14/11/202401:14Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MXCTMaxCyte Inc
13/11/202414:05GlobeNewswire Inc.MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsNASDAQ:MXCTMaxCyte Inc
06/11/202422:55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MXCTMaxCyte Inc
06/11/202422:05GlobeNewswire Inc.MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
31/10/202413:05GlobeNewswire Inc.MaxCyte to Participate in Two Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
16/10/202423:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
15/10/202414:05GlobeNewswire Inc.MaxCyte Appoints Cynthia Collins to its Board of DirectorsNASDAQ:MXCTMaxCyte Inc
11/10/202414:05GlobeNewswire Inc.MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024NASDAQ:MXCTMaxCyte Inc
10/10/202414:05GlobeNewswire Inc.MaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerNASDAQ:MXCTMaxCyte Inc
26/09/202422:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MXCTMaxCyte Inc
16/09/202408:00GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesNASDAQ:MXCTMaxCyte Inc
05/09/202422:05GlobeNewswire Inc.MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing ConferenceNASDAQ:MXCTMaxCyte Inc
06/08/202422:05GlobeNewswire Inc.MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
09/07/202422:05GlobeNewswire Inc.MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:MXCTMaxCyte Inc
29/05/202414:05GlobeNewswire Inc.MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceNASDAQ:MXCTMaxCyte Inc
22/05/202414:05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentNASDAQ:MXCTMaxCyte Inc
07/05/202422:05GlobeNewswire Inc.MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
10/04/202414:05GlobeNewswire Inc.MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024NASDAQ:MXCTMaxCyte Inc
02/04/202414:05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)NASDAQ:MXCTMaxCyte Inc
12/03/202421:05GlobeNewswire Inc.MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
04/03/202422:05GlobeNewswire Inc.MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsNASDAQ:MXCTMaxCyte Inc
14/02/202422:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MXCTMaxCyte Inc
14/02/202418:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MXCTMaxCyte Inc
09/02/202414:05GlobeNewswire Inc.MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
30/01/202414:05GlobeNewswire Inc.MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersNASDAQ:MXCTMaxCyte Inc
23/01/202414:05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsNASDAQ:MXCTMaxCyte Inc
08/01/202422:05GlobeNewswire Inc.MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MXCTMaxCyte Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MXCT

La tua Cronologia

BIT
IEAC
Exchange Traded
BIT
I07276
INTESA SANPAOLO
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network